NL-OMON44998CompletedNot Applicable
A treatment algorithm for Hepatic Angiomyolipomas: a long-term follow-up study and a systematic review - Managment of Hepatic Angiomyolipoma's
Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites9 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 9
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Eighteen years or older;
- •Diagnosis of HAML either by MRI, biopsy or after tumor resection;
- •Previous MRI scan with baseline characteristics for patients who received a non-surgical treatment.
Exclusion Criteria
- •Contrast allergy;
- •MRI contraindication (e.g. pacemaker, metal)
- •Renal failure.
Investigators
Similar Trials
Recruiting
Not Applicable
THIAMAT-Local Ablative Therapy of Hepatic Malignomas - Proximity to untreated tumor tissueHepatic metastatic colorectal cancerC50C22Malignant neoplasm of breastMalignant neoplasm of liver and intrahepatic bile ductsDRKS00010560Klinik und Poliklinik für Radiologie Klinikum der Universität München100
Terminated
Phase 2
Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockersRenal AngiomyolipomasTuberous SclerosisNCT02104011University Hospital, Bordeaux2
Recruiting
Not Applicable
Sequential therapy for hepatocellular carcinoma -Real world evidence of TKI in prospective observational studyhepatocellular carcinomaJPRN-UMIN000038867Kyushu Study group of Clinical Cancer500
Completed
Not Applicable
Effectiveness of Renal Angiomyolipoma Embolization Using Polyvinyl Alcohol (PVA): A Retrospective Review at Phramongkutklao Hospital Between 2011-2018Clinical and radiographic outcome after embolization with PVAMinor and Major complication from treatmentAngiomyolipoma,AML,Renal,Embolization,Polyvinyl alcohol,PVATCTR20200212002none9
Not yet recruiting
Not Applicable
Choices of therapeutic strategies for hepatocellular carcinoma (HCC)C22.0Liver cell carcinomaDRKS00025099Chirurgische Klinik, Universitätsmedizin Mannheim200